Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy
Perry B. Shieh
Neurotherapeutics (2018) Vol. 15, Iss. 4, pp. 840-848
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

The promise and challenge of therapeutic genome editing
Jennifer A. Doudna
Nature (2020) Vol. 578, Iss. 7794, pp. 229-236
Open Access | Times Cited: 907
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
F. Fortunato, Rachele Rossi, Maria Sofia Falzarano, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 820-820
Open Access | Times Cited: 57
Muscle cell‐derived cytokines in skeletal muscle regeneration
Rachel J. Waldemer, Dong‐Wook Kim, Jie Chen
FEBS Journal (2022) Vol. 289, Iss. 21, pp. 6463-6483
Open Access | Times Cited: 42
Idebenone attenuates ferroptosis by inhibiting excessive autophagy via the ROS-AMPK-mTOR pathway to preserve cardiac function after myocardial infarction
Demin Li, Ge Zhang, Zeyu Wang, et al.
European Journal of Pharmacology (2023) Vol. 943, pp. 175569-175569
Open Access | Times Cited: 35
Hypoxia-associated autophagy flux dysregulation in human cancers
Jiding Fu, Jie Lin, Zili Dai, et al.
Cancer Letters (2024) Vol. 590, pp. 216823-216823
Closed Access | Times Cited: 8
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Angela Sang, S. Zhuo, Adara Bochanis, et al.
BioDrugs (2024) Vol. 38, Iss. 4, pp. 511-526
Closed Access | Times Cited: 7
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy
Giorgia Careccia, Marielle Saclier, Mario Tirone, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 596
Closed Access | Times Cited: 39
Duchenne muscular dystrophy: promising early-stage clinical trials to watch
Annie Tang, Toshifumi Yokota
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 201-217
Closed Access | Times Cited: 5
New insights into the function of the NLRP3 inflammasome in sarcopenia: mechanism and therapeutic strategies
Yunyi Zou, Xiangbin Tang, Siyuan Yang, et al.
Metabolism (2024) Vol. 158, pp. 155972-155972
Closed Access | Times Cited: 5
Genome editing for Duchenne muscular dystrophy: a glimpse of the future?
Christian Kupatt, Alina Windisch, Alessandra Moretti, et al.
Gene Therapy (2021) Vol. 28, Iss. 9, pp. 542-548
Open Access | Times Cited: 29
Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy
Michela Ripolone, Daniele Velardo, Stefania Mondello, et al.
Acta Neuropathologica Communications (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 22
Immune-mediated myositis following gene therapy for Duchenne muscular dystrophy: a case report
Susan T. Iannaccone, Chunyu Cai, Brittney Rhem, et al.
Journal of Neurology (2024) Vol. 271, Iss. 8, pp. 5659-5664
Open Access | Times Cited: 4
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
Akinori Nakamura
Journal of Personalized Medicine (2019) Vol. 9, Iss. 1, pp. 16-16
Open Access | Times Cited: 35
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy
Jeffrey Statland, Craig Campbell, Urvi Desai, et al.
Muscle & Nerve (2022) Vol. 66, Iss. 1, pp. 50-62
Open Access | Times Cited: 19
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies
Jaeho Hwang, Toshifumi Yokota
Expert Reviews in Molecular Medicine (2019) Vol. 21
Closed Access | Times Cited: 29
Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia
Monica Borgatti, Emiliano Altamura, Francesca Salvatori, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 2, pp. 289-289
Open Access | Times Cited: 27
Lessons for future clinical trials in adults with Becker muscular dystrophy: Disease progression detected by muscle magnetic resonance imaging, clinical and patient‐reported outcome measures
Bram De Wel, L. Iterbeke, Lotte Huysmans, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 7
Open Access | Times Cited: 3
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy
Lakshmi Krishna, Akila Prashant, Yogish H. Kumar, et al.
Neurology International (2024) Vol. 16, Iss. 4, pp. 731-760
Open Access | Times Cited: 3
Advancements in magnetic resonance imaging‐based biomarkers for muscular dystrophy
Doris Leung
Muscle & Nerve (2019) Vol. 60, Iss. 4, pp. 347-360
Open Access | Times Cited: 23
The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin–lysophosphatidic acid as a new therapeutic target?
Felipe S. Gallardo, Adriana Córdova-Casanova, Enrique Brandan
Journal of Cell Communication and Signaling (2021) Vol. 15, Iss. 3, pp. 317-334
Open Access | Times Cited: 20
Synergistic short-term and long-term effects of TGF-β1 and 3 on collagen production in differentiating myoblasts
Andi Shi, Michèle MG Hillege, Rob C. I. Wüst, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 547, pp. 176-182
Open Access | Times Cited: 18
Regulation of the dystrophin-associated glycoprotein complex composition by the metabolic properties of muscle fibres
Saleh Omairi, Kwan-Leong Hau, Henry Collins‐Hooper, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 18
“Betwixt Mine Eye and Heart a League Is Took”: The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy
Davide Rovina, Elisa Castiglioni, Francesco Niro, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 6997-6997
Open Access | Times Cited: 18
Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
Pablo Beckers, Jean‐Hubert Caberg, Vinciane Dideberg, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 15
Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases
Christine Péladeau, Jagdeep K. Sandhu
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 6068-6068
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top